OnKure Therapeutics
Boulder
About OnKure Therapeutics
OnKure is a biotechnology company that commercializes a new cancer therapy based on novel, less toxic kinase inhibitor drugs. The company is engaged in the discovery and development of epigenetic therapies for the treatment of cancer that includes selective inhibitors of histone deacetylases. In pre-clinical models of both hematological and solid tumor cancers, their lead candidate, OKI-179, significantly and safely reduces the growth rate of tumors when dosed by itself or in combination with other targeted therapies. OnKure advances the HDAC3 selective inhibitor OKI-422 into pre-clinical toxicology studies. The company's drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $336.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2026)
- Ticker: nasdaq:OKUR
- Website: onkuretherapeutics.com
- Phone: 720-307-2892
Industries & Categories
Biotechnology, Life Science, Precision Medicine, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/onkure-therapeutics-54427 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.